查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813889

美国遗传性癌症检测市场规模、份额和趋势分析报告：按癌症类型、技术、检测类型、最终用途和细分市场预测，2025-2033 年

U.S. Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End-use, And Segment Forecasts, 2025 to 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

美国遗传性癌症检测市场规模预计在 2024 年达到 19.3 亿美元，预计到 2033 年将达到 57.6 亿美元，2025 年至 2033 年的复合年增长率为 13.32%。

美国遗传性癌症检测市场的成长动力源自于人们对遗传性癌症风险日益增长的认识，5-10% 的癌症与生殖系突变有关。 NCCN 和 ACOG 指南筛检的采用率不断提高，加上 FDA 专家小组的批准，正在提升临床医生的信心并扩大支付方覆盖范围。 DNA/RNA 整合定序、数位筛检工具以及生殖系和体细胞分析等技术进步正在扩大临床效用。加强伙伴关係、开展病患教育计画以及提供保险支持，正在进一步加速基因检测的可及性，并将基因检测定位为精准肿瘤学的基石。

在美国，5–10% 的癌症与癌症易感基因的遗传突变有关。这些遗传突变透过家族遗传，增加了乳癌、卵巢、大肠癌和摄护腺癌等癌症的风险。虽然大多数乳癌病例（估计有 27 万名女性、2,000 名男性和 20,000 例卵巢癌病例）每年发生，但这些病例是偶发的，但很大一部分是遗传性的。这凸显了基因检测作为早期发现和预防性医疗保健工具的重要性。美国国家综合癌症网络 (NCCN) 已製定指南，主要根据个人和家族癌症史来识别最有可能携带突变的个体。然而，儘管这些指南很有力度，但基因检测历来未充分利用，部分原因是各实验室的解释不一致以及患者获得检测的机会有限。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国遗传性癌症检测市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场前景。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国遗传性癌症检测市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国遗传性癌症检测市场：癌症估计与趋势分析

  • 细分仪表板
  • 美国遗传性癌症检测市场：癌症变异分析
  • 美国遗传性癌症检测市场规模与趋势分析（按癌症类型，2021-2033 年）
  • 2021-2033年美国遗传性癌症检测市场收益估计与预测
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 卵巢癌
  • 摄护腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宫癌
  • 胰臟癌
  • 其他的

第五章美国遗传性癌症检测市场：技术评估与趋势分析

  • 2024年及2033年技术市场份额
  • 细分仪表板
  • 美国遗传性癌症检测市场：技术展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 细胞遗传学
  • 生化
  • 分子检测

第六章美国遗传性癌症检测市场：检测类型估计与趋势分析

  • 2024 年和 2033 年测试类型市场份额
  • 细分仪表板
  • 按测试类型分類的市场前景
  • 2021年至2033年市场规模、预测与趋势分析
  • 预测测试
  • 诊断测试

第七章美国遗传性癌症检测市场：最终用途估计与趋势分析

  • 2024年和2033年的最终用途市场份额
  • 细分仪表板
  • 按最终用途分類的市场前景
  • 2021年至2033年市场规模、预测与趋势分析
  • 诊断中心
  • 医院
  • 诊所

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 2024年主要企业市场占有率分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-721-8

Market Size & Trends:

The U.S. hereditary cancer testing market was estimated at USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 13.32% from 2025 to 2033. The U.S. hereditary cancer testing market is driven by growing awareness of inherited cancer risks, with 5-10% of cancers linked to germline mutations. Rising adoption of guideline-based screening from NCCN and ACOG, coupled with FDA authorization of panels, is boosting clinician confidence and payer coverage. Technological advancements such as integration of DNA/RNA sequencing, digital screening tools, and combined germline-somatic profiling are expanding clinical utility. Increasing partnerships, patient education initiatives, and insurance support are further accelerating access, positioning hereditary testing as a cornerstone of precision oncology.

In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.

U.S. Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the hereditary cancer testing market report on the basis of test type, technology, cancer, andend-use:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Stomach/Gastric Cancer
  • Melanoma
  • Sarcoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Predictive Testing
  • Diagnostic Testing
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostic Centers
  • Hospitals
  • Clinics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. U.S. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. U.S. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
  • 4.4. U.S. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Myriad Genetics, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Invitae Corporation
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bio-Rad Laboratories
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. CSL Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Qiagen NV
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Danaher Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Thermo Fisher Scientific
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Abbott Laboratories
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. EUROFINS SCIENTIFIC
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. F. HOFFMANN-LA ROCHE LTD
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Illumina, Inc.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Services benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
  • Table 3 U.S Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 U.S Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
  • Table 5 U.S Hereditary cancer testing market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig.1 Market research process
  • Fig.2 Data triangulation techniques
  • Fig.3 Primary research pattern
  • Fig.4 Primary interviews in North America
  • Fig.5 Primary interviews in Europe
  • Fig.6 Primary interviews in APAC
  • Fig.7 Primary interviews in Latin America
  • Fig.8 Primary interviews in MEA
  • Fig.9 Market research approaches
  • Fig.10 Value-chain-based sizing & forecasting
  • Fig.11 QFD modeling for market share assessment
  • Fig.12 Market formulation & validation
  • Fig.13 Hereditary cancer testing market: market outlook
  • Fig.14 Hereditary cancer testing competitive insights
  • Fig.15 Parent market outlook
  • Fig.16 Related/ancillary market outlook
  • Fig.17 Penetration and growth prospect mapping
  • Fig.18 Industry value chain analysis
  • Fig.19 Hereditary cancer testing market driver impact
  • Fig.20 Hereditary cancer testing market restraint impact
  • Fig.21 Hereditary cancer testing market strategic initiatives analysis
  • Fig.22 Hereditary cancer testing market: Cancer movement analysis
  • Fig.23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig.24 Hereditary cancer Testing market estimates and forecast, 2021 - 2033
  • Fig.25 Hereditary cancer testing Market: Technology movement analysis
  • Fig.26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig.27 Cytogenetic market estimates and forecasts, 2021 - 2033
  • Fig.28 Biochemical market estimates and forecasts,2021 - 2033
  • Fig.29 Molecular Testing market estimates and forecasts,2021 - 2033
  • Fig.30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig.31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig.32 Predictive Testing market estimates and forecasts, 2021 - 2033
  • Fig.33 Diagnostic Testing market estimates and forecasts, 2021 - 2033
  • Fig.34 Hereditary cancer testing Market: End Use movement analysis
  • Fig.35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig.36 Diagnostic Centers market estimates and forecasts, 2021 - 2033
  • Fig.37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig.38 Clinics market estimates and forecasts, 2021 - 2033
  • Fig.39 Market share of key market players- Hereditary cancer testing market